GILD241011C84000
- 1.25
- -0.09-6.72%
Gilead Sciences Newsroom
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Gilead Sciences Analyst Ratings
Gilead Upgraded to Overweight by Wells Fargo, PrEP Launch Cited
Wells Fargo Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $100
Gilead Sciences (GILD) Was Upgraded to a Buy Rating at Wells Fargo
Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD)
Gilead Sciences Analyst Ratings
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $123 From $119, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies Remains a Buy on Gilead Sciences (GILD)
J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating
Buy Rating on Gilead Sciences: Underestimated Market Potential of Lenacapavir in HIV Treatment and Prevention
Hold Rating on Gilead Sciences Amid Lenacapavir's Promise and Market Uncertainties
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $90
J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating
Buy Rating Affirmed for Gilead Sciences on Lenacapavir's Market-Changing Potential in PrEP